Disc Medicine Q2 net loss $15.9M, cash $378M; BEACON bitopertin data positive

Disc Medicine, Inc.

2023-Q2 EPS reported -$1.91

Net loss $15.9M in Q2 2023 vs $9.6M in Q2 2022; R&D expense $12.1M, G&A $5.2M.
Cash and equivalents $377.6M as of June 30, 2023; expected to fund operations into 2026.
BEACON Phase 2 bitopertin data showed dose-dependent PPIX reduction, improved sunlight tolerance; well-tolerated.
Enrolling two Phase 1b/2 studies for DISC-0974 (NDD-CKD and myelofibrosis); initial data expected year-end 2023.
Completed upsized public offering in June 2023 for $157.8M gross proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Disc Medicine, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $15.9 million for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Net income: Net loss was $15.9 million for the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Disc Medicine, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2023 and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Disc Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209833

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.